MEGGLE's outstanding product quality and intelligent approach to innovation has secured it a place as a global leader in the manufacture of lactose-based excipients. In this segment, we focus on the production of excipients for direct tabletting and dry powder inhalation. We have now spent over 70 years in developing a broad-based product portfolio that is unique in its market, a fact eloquently confirmed by numerous first-to-market launches. These include:
- Tablettose: first agglomerated lactose for direct tabletting
- Cellactose 80: first co-processed excipient using a cellulose-lactose base with outstanding compression and flow properties
- RetaLac: first co-processed excipient using a hypromellose-lactose base for extended release formulations used in direct tabletting
For us, it is both an obligation and an opportunity to provide our customers with professional support in the areas of drug formulation, information services and production optimisation.
Our experienced and highly qualified employees work for our customers worldwide. This means that our customers can count on our services in different time zones and at many locations around the world. This includes multilingual support for the development of new markets and segments as well as for further application areas and business strategies. We also have several independent application labs in Germany, Brazil and China.
We are also a competent partner for the university sector. Therefore, we maintain close cooperation with scientists from universities and colleges. In addition, we support and supervise a large number of final theses and dissertations.
"We believe excipient optimisation will continue to show major potential in the future: this is both the justification and motivation for our day-to-day work."